Noopept and Selank Interaction: Compatible | Peptide Database

Reduces estradiol levels during testosterone or aromatizable anabolic steroid cycles to prevent the development of estrogen-driven breast tissue growth. Most effective when started proactively rather than reactively. Manages estrogen-mediated fluid retention and subcutaneous bloating that commonly accompanies testosterone or other aromatizable compounds, contributing to a leaner appearance and reduced blood pressure. Titrated at low doses to keep estradiol within a target range (typically 20-40 pg/mL in men) during hormone replacement or enhancement protocols. Requires bloodwork for proper calibration. FDA-approved as adjuvant and first-line treatment for hormone receptor-positive breast cancer in postmenopausal women. Demonstrated superior disease-free survival compared to tamoxifen in the landmark ATAC trial. Used off-label alongside TRT to manage estradiol elevations, particularly in men with high body fat who aromatize testosterone more readily. Some clinicians prescribe low-dose anastrozole as part of comprehensive TRT protocols. Helps maintain a favorable testosterone-to-estradiol ratio in men on supraphysiological testosterone doses. An excessively high ratio (crashed estrogen) is as problematic as a low ratio, so careful dosing is essential. Some men aromatize testosterone at higher rates due to genetics or elevated body fat. Low-dose anastrozole can help these individuals manage estrogen even on standard TRT doses.

Multiple randomized controlled trials have demonstrated that berberine (500 mg 2-3x daily) reduces fasting blood glucose by 15-25% and HbA1c by 0.5-0.9% in individuals with type 2 diabetes or insulin resistance. A landmark 2008 study in Metabolism showed berberine was comparable to metformin in glycemic control over a 3-month period. Particularly useful for individuals seeking a non-prescription approach to glucose management. Berberine consistently reduces total cholesterol by 15-20%, LDL cholesterol by 20-25%, and triglycerides by 25-35% across clinical trials. Its PCSK9-inhibitory activity provides a unique lipid-lowering mechanism distinct from statins. May be used alone or as adjunctive therapy alongside other lipid-lowering interventions. Improves insulin sensitivity through multiple mechanisms including AMPK activation and insulin receptor upregulation. Reduces HOMA-IR scores in clinical studies. A practical option for individuals with prediabetes or metabolic syndrome who prefer a supplement-based approach before initiating pharmaceutical therapy. Widely used in the biohacking community to counteract the blood glucose elevations associated with MK-677 (ibutamoren) and exogenous growth hormone use. MK-677 can raise fasting glucose by 5-15 mg/dL through GH-mediated insulin resistance, and berberine's AMPK activation helps offset this effect. Often dosed at 500 mg with the evening meal when MK-677 is taken at night. AMPK activity declines with age, contributing to metabolic dysfunction, reduced autophagy, and increased inflammation. Berberine's potent AMPK activation may help counteract age-related metabolic decline. Preclinical studies suggest berberine extends lifespan in several model organisms, though human longevity data is limited to indirect metabolic biomarker improvements. The combination of glucose-lowering, lipid-lowering, and anti-inflammatory effects positions berberine as a compound with potential cardiovascular benefits. Clinical trials have shown improvements in endothelial function and reductions in carotid intima-media thickness. However, long-term cardiovascular outcome trials have not been conducted. Berberine has demonstrated significant effects on gut microbiota composition, increasing populations of Akkermansia muciniphila and other beneficial bacteria associated with improved metabolic health. These microbiome changes may account for a meaningful portion of berberine's systemic metabolic effects, as much of the compound remains in the gut due to its low oral bioavailability.